Inovio Pharmaceuticals EBIT

The latest EBIT for GBM.F is $-87B as of June 2026. That compares with $-52B in the prior-year period — down 65.5% year over year. That is below the Industrials sector average of $190B. Investors often review this figure alongside Inovio Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, GBM.F's EBIT moved from $-52B to $-87B — a 65.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Inovio Pharmaceuticals's operating scale or balance-sheet position.

Against Industrials companies, GBM.F currently prints $-87B for EBIT, while the sector average sits near $190B. That is roughly 146.4% below the sector mean. Large gaps often invite a closer look at Inovio Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-87B for GBM.F is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Industrials average is about $190B. Explore the charts below for those layers of context.

After noting GBM.F's EBIT ($-87B), review year-over-year change from $-52B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.